Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445514 in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
NCT05839626Phase 1Terminated
- Sponsor
- Sanofi
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Trispecific Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of SAR445514 in multiple myeloma (MM) and light-chain amyloidosis (6 arms), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Treatment-Emergent Adverse Events at 15 months and 2 more. Started May 2023; status: terminated.
02
Drugs
SAR445514
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT05839626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839626.